Advanced search
Publication Cover
HIV Clinical Trials Volume 13, 2012 - Issue 2
Submit an article Journal homepage
55
Views
18
CrossRef citations to date
0
Altmetric
Original Articles

Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients

Juan MacíasUnit of Infectious Diseases and MicrobiologyHospital Universitario de Valme, Seville, Spain
,
Karin NeukamUnit of Infectious Diseases and MicrobiologyHospital Universitario de Valme, Seville, Spain
,
Josep MallolasUnit of Infectious DiseasesHospital Clínic, Barcelona, Spain
,
Luis F. López-CortésUnit of Infectious DiseasesHospitales Universitarios Virgen Rocío, Seville, Spain
,
José A. CartónUnit of Infectious DiseasesHospital Central de Asturias, Oviedo, Spain
,
Pere DomingoDepartment of Internal MedicineHospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain
,
Santiago MorenoDepartment of Infectious DiseasesHospital Universitario Ramón y Cajal, Madrid, Spain
,
José A. IribarrenUnit of Infectious DiseasesHospital Donostia, San Sebastian, Spain
,
Bonaventura ClotetUnit of HIVHospital Germans Trias i Pujol, Badalona, Spain
,
Manell CrespoUnit of Infectious DiseasesHospital Vall d’Hebron, Barcelona, Spain
,
Ignacio de Los SantosUnit of Infectious Diseases, Hospital Universitario de La Princesa, Madrid, Spain
,
Enrique OrtegaUnit of Infectious Diseases, Hospital General Universitario de Valencia, Valencia, Spain
,
Hernando KnobelDepartment of Infectious Diseases, Hospital del Mar, Barcelona, Spain
,
María J. Jiménez-ExpósitoBristol-Meyers Squibb, Madrid, Spain
,
Juan A. PinedaUnit of Infectious Diseases and MicrobiologyHospital Universitario de Valme, Seville, SpainCorrespondence[email protected]
& on behalf of the COINS Study Team show all
Pages 61-69 | Published online: 06 Jan 2015

REFERENCES

  • Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22:1979–1991.
  • Macias J, Berenguer J, Japón MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology. 2009;50:1056–1063.
  • Pineda JA, Garcia-Garcia JA, Aguilar-Guisado M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology. 2007;46:622–630.
  • Dieleman JP, Jambroes M, Gyssens IC, et al. Deter-minants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS. 2002;16:737–745.
  • Jain MK. Drug-induced liver injury associated with HIV medications. Clin Liver Dis. 2007;11:615–639.
  • Soriano V, Koeppe S, Mingrone H, et al. Prospective comparison of nevirapine and atazanavir/ritonavir both combined with tenofovir DF/emtricitabine in treatment-naïve HIV-1 infected patients: ARTEN study week 48 results. Presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Preven-tion (IAS) 2009; July 19–22, 2009; Cape Town, South Africa. Abstract LBPEB07.
  • van Leth F, Phanuphak P, Ruxrungthan K, et al. Compari-son of first-line antiretroviral therapy with regimens includ-ing nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN study. Lancet. 2004;363:1253–1263.
  • da Silva B, King M, Cernohous P, et al. Lopinavir/ritona-vir (LPV/r) safety, tolerability and efficacy in HIV patients co-infected with hepatitis C and/or hepatitis B: review of clinical trials. In: Program and abstracts of the The XV International AIDS Conference; 2004; Bangkok. Abstract MoPeB3285.
  • Norris D, Patel L, Rizzardini G, et al. Efficacy and safety of fosamprenavir/ritonavir (FPV/r) bid or lopinavir/ritona-vir (LPV/r) bid in antiretroviral treatment-naïve subjects co-infected with hepatitis B (HBV) or C (HCV) and HIV (the KLEAN study). In: Program and abstracts of the 4th International AIDS Society (IAS) Conference on HIV Pathogenenesis, Treatment and Prevention; 2007; Sydney. Abstract MOPEB059.
  • Absalon J, Thal G, Thiry A, et al. Atazanavir is safe and effi-cacious in HBV and HCV co-infected patients: results of A1424138 (CASTLE). In: Program and abstracts of the 9th International Congress on Drug Therapy in HIV Infection; 2008; Glasgow. Abstract P136.
  • Ortiz R, Fourie J, Andrade-Villanueva J, et al. Tolerability of once-daily darunavir/r versus lopinavir/r in treatment naive patients coinfected with hepatitis B and/or C in the ARTEMIS trial. In: Program and abstracts of the HEP DART: Frontiers in Drug Development for Viral Hepatitis; 2007; Hawaü. Abstract 97.
  • Pineda JA, Santos J, Rivero A, et al. Liver toxicity of anti-retroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis. J Antimicrob Chemother. 2008;61:925–932.
  • Palacios R, Vergara S, Rivero A, et al. Low incidence of severe liver events in HIV patients with and without hepati-tis C or B coinfection receiving lopinavir/ritonavir. HIV Clin Trials. 2006;7:319–323.
  • Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182–189.
  • Martin-Carbonero L, Nunez M, González-Lahoz, et al. Incidence of liver injury after beginning antiretrovi-ral therapy with efavirenz or nevirapine. HIV Clin Trials. 2003;4:115–278.
  • Martinez E, Blanco J, Arnaiz J, et al. Hepatotoxicity in HIV-infected patients receiving nevirapine containing anti-retroviral therapy. AIDS. 2001;15:1261–1268.
  • Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372–374.
  • Sustiva [efavirenz] capsules and tablet. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). March 2010. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm208409.htm. Accessed at May 18,2010.
  • FDA Public Health Advisory for nevirapine [Viramune]. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAd-visories/ucm051674.htm. Accessed at May 18, 2010.
  • Chalasani N, Bjärnsson E. Risk factors for idiosyn-cratic drug-induced liver injury. Gastroenterology. 2010;138:2246–2259.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.